EE200300049A - Imidasooli derivaadid - Google Patents

Imidasooli derivaadid

Info

Publication number: EE200300049A
Authority: EE; Estonia
Prior art keywords: imidazole derivatives; imidazole; derivatives
Prior art date: 2000-07-31

Application number

EEP200300049A

Other languages

English (en)

Inventor

Kirk Ahlijanian Michael

Blair Cooper Christopher

John Helal Christopher

Lau Lit-Fui

Samuel Menniti Frank

Allen Sanner Mark

Ann Seymour Patricia

Villalobos Anabella

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-31

Filing date

2001-07-25

Publication date

2004-10-15

2001-07-25 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-10-15 Publication of EE200300049A publication Critical patent/EE200300049A/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Gynecology & Obstetrics (AREA)

EEP200300049A 2000-07-31 2001-07-25 Imidasooli derivaadid EE200300049A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22172400P	2000-07-31	2000-07-31
PCT/IB2001/001335 WO2002010141A1 (en)	2000-07-31	2001-07-25	Imidazole derivatives

Publications (1)

Publication Number	Publication Date
EE200300049A true EE200300049A (et)	2004-10-15

Family

ID=22829075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300049A EE200300049A (et)	2000-07-31	2001-07-25	Imidasooli derivaadid

Country Status (35)

Country	Link
EP (1)	EP1305295A1 (et)
JP (2)	JP4166084B2 (et)
KR (1)	KR20030019644A (et)
CN (1)	CN1444567A (et)
AP (1)	AP2001002232A0 (et)
AR (1)	AR032629A1 (et)
AU (1)	AU2001270944A1 (et)
BG (1)	BG107469A (et)
BR (1)	BR0112862A (et)
CA (1)	CA2418115A1 (et)
CR (1)	CR6861A (et)
CZ (1)	CZ2003225A3 (et)
DO (1)	DOP2001000220A (et)
EA (1)	EA200300097A1 (et)
EC (1)	ECSP034445A (et)
EE (1)	EE200300049A (et)
GT (1)	GT200100147A (et)
HR (1)	HRP20030048A2 (et)
HU (1)	HUP0303069A3 (et)
IL (1)	IL153787A0 (et)
IS (1)	IS6662A (et)
MA (1)	MA26932A1 (et)
MX (1)	MXPA03000939A (et)
NO (1)	NO20030472L (et)
NZ (1)	NZ523272A (et)
OA (1)	OA12345A (et)
PA (1)	PA8523701A1 (et)
PE (1)	PE20020337A1 (et)
PL (1)	PL365134A1 (et)
SK (1)	SK1042003A3 (et)
SV (1)	SV2002000571A (et)
TN (1)	TNSN01114A1 (et)
UY (1)	UY26862A1 (et)
WO (1)	WO2002010141A1 (et)
ZA (1)	ZA200300819B (et)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE538794T1 (de)	1999-01-13	2012-01-15	Bayer Healthcare Llc	Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (es)	2002-02-11	2005-09-08	Bayer Pharmaceuticals Corp	Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003068229A1 (en)	2002-02-11	2003-08-21	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7465736B2 (en)	2002-06-14	2008-12-16	Laboratoires Serono S.A.	Azole methylidene cyanide derivatives and their use as protein kinase modulators
US7141561B2 (en)	2002-07-25	2006-11-28	Sanofi-Aventis Deutschland Gmbh	Substituted diaryl heterocycles, process for their preparation and their use as medicaments
DE10233817A1 (de) *	2002-07-25	2004-02-12	Aventis Pharma Deutschland Gmbh	Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0308968D0 (en) *	2003-04-17	2003-05-28	Glaxo Group Ltd	Medicaments
EP1636585B2 (en)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr)	2003-07-23	2014-03-14	Bayer Healthcare Llc	Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
SI1730119T1 (sl) *	2004-03-23	2008-10-31	Pfizer Prod Inc	Spojine imidazola za zdravljenje nevrodegenerativnih obolenj
CN101010315A (zh)	2004-04-30	2007-08-01	拜耳制药公司	用于治疗癌症的取代的吡唑基脲衍生物
US7928264B2 (en)	2004-09-21	2011-04-19	Astellas Pharma Inc.	Aminoalcohol derivatives
WO2006117212A2 (en)	2005-05-04	2006-11-09	Develogen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
JP2009508934A (ja)	2005-09-22	2009-03-05	ファイザー・プロダクツ・インク	神経障害治療のためのイミダゾール化合物
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
WO2007084391A2 (en)	2006-01-18	2007-07-26	Amgen Inc.	Thiazole compounds as protein kinase b ( pkb) inhibitors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
EP2535336A1 (en)	2006-10-21	2012-12-19	Abbott GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009017453A1 (en) *	2007-07-30	2009-02-05	Astrazeneca Ab	New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
MX2010011663A (es) *	2008-04-24	2011-01-21	Abbott Gmbh & Co Kg	Derivados de 1-(7-hexahidropirrolo [3,4-c] pirrol-2 (1h)-il) quinolin-3-il)-(pirazin-2-il) urea y compuestos relacionados como glicogeno sintasa quinasa 3 (gsk-3).
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP2621914B1 (en)	2010-09-27	2016-12-28	Abbott GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en)	2010-12-30	2015-07-28	AbbVie Deutschland GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2014089495A1 (en)	2012-12-07	2014-06-12	Chemocentryx, Inc.	Diazole lactams
EP2935227B1 (en)	2012-12-21	2017-09-13	ChemoCentryx, Inc.	Diazole amides as ccr1 receptor antagonists
EP3103455A4 (en) *	2014-02-07	2017-10-04	National University Corporation Tokyo Medical and Dental University	Myogenesis accelerator, amyotrophy suppressor, medicinal composition, and taz activator
EP3662919A1 (en) *	2015-08-31	2020-06-10	Nutramax Laboratories, Inc.	Compositions comprising magnolia, phellodendron, theanine and/or whey protein
GB201605126D0 (en) *	2016-03-24	2016-05-11	Univ Nottingham	Inhibitors and their uses
PL3439653T3 (pl)	2016-04-07	2021-07-05	Chemocentryx, Inc.	Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1
CN107698567B (zh) *	2017-10-25	2020-09-15	西南大学	靛红唑醇类化合物及其制备方法和医药应用
EP3818044A1 (en) *	2018-07-03	2021-05-12	IFM Due, Inc.	Compounds and compositions for treating conditions associated with sting activity
JP2022520671A (ja)	2019-02-08	2022-03-31	フリークエンシー・セラピューティクス・インコーポレイテッド	耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
GB201908424D0 (en) *	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
KR20250030524A (ko)	2019-08-09	2025-03-05	화이자 인코포레이티드	(s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도
US11884634B2 (en)	2019-08-09	2024-01-30	Pfizer Inc.	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
CN116568671A (zh) *	2020-10-16	2023-08-08	分子医学研究中心责任有限公司	杂环Cullin-RING泛素连接酶化合物及其用途
CN112250636A (zh) *	2020-11-09	2021-01-22	广西科技大学	5-氨基咪唑类化合物及其合成方法
US12097261B2 (en)	2021-05-07	2024-09-24	Kymera Therapeutics, Inc.	CDK2 degraders and uses thereof
PE20241348A1 (es)	2021-09-01	2024-07-03	Springworks Therapeutics Inc	Sintesis de nirogacestat
US11504354B1 (en)	2021-09-08	2022-11-22	SpringWorks Therapeutics Inc..	Chlorinated tetralin compounds and pharmaceutical compositions
CN116983313A (zh) *	2023-07-13	2023-11-03	四川大学	Nu6300的新用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5401851A (en) *	1992-06-03	1995-03-28	Eli Lilly And Company	Angiotensin II antagonists
US5760246A (en) *	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en) *	1997-08-19	2000-04-18	Lilly Co Eli	Growth hormone secretagogues.
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
JP4533534B2 (ja) *	1998-06-19	2010-09-01	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	グリコーゲンシンターゼキナーゼ３のインヒビター
WO2000021550A2 (en) *	1998-10-13	2000-04-20	President And Fellows Of Harvard College	Methods and compositions for treating neurodegenerative diseases
CO5160260A1 (es) *	1999-02-19	2002-05-30	Lilly Co Eli	Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
ATE253918T1 (de) *	1999-12-08	2003-11-15	Centre Nat Rech Scient	Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel

2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/es unknown
- 2001-07-25 CN CN01813397A patent/CN1444567A/zh active Pending
- 2001-07-25 IL IL15378701A patent/IL153787A0/xx unknown
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/hu unknown
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 EE EEP200300049A patent/EE200300049A/et unknown
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/ja not_active Expired - Fee Related
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Ceased
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/es active IP Right Grant
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/pt not_active IP Right Cessation
- 2001-07-25 PL PL01365134A patent/PL365134A1/xx not_active Application Discontinuation
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 EA EA200300097A patent/EA200300097A1/ru unknown
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/ko not_active Ceased
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/es not_active Application Discontinuation
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/sk not_active Application Discontinuation
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/cs unknown
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 HR HR20030048A patent/HRP20030048A2/hr not_active Application Discontinuation
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/es unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/es not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/fr unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/es unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/es not_active Application Discontinuation
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/es unknown
2002
- 2002-12-18 CR CR6861A patent/CR6861A/es not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/is unknown
2003
- 2003-01-16 BG BG107469A patent/BG107469A/bg unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/fr unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/es unknown
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/no not_active Application Discontinuation
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
BR0112862A (pt)	2003-07-01
SK1042003A3 (en)	2004-05-04
GT200100147A (es)	2002-06-25
PA8523701A1 (es)	2002-04-25
HUP0303069A3 (en)	2004-04-28
JP4166084B2 (ja)	2008-10-15
AP2001002232A0 (en)	2001-09-30
CA2418115A1 (en)	2002-02-07
HRP20030048A2 (en)	2003-04-30
MA26932A1 (fr)	2004-12-20
EA200300097A1 (ru)	2003-06-26
EP1305295A1 (en)	2003-05-02
OA12345A (en)	2004-04-13
CZ2003225A3 (cs)	2004-02-18
CN1444567A (zh)	2003-09-24
WO2002010141A1 (en)	2002-02-07
JP2004505111A (ja)	2004-02-19
SV2002000571A (es)	2002-10-24
NO20030472D0 (no)	2003-01-30
AR032629A1 (es)	2003-11-19
MXPA03000939A (es)	2003-06-24
IL153787A0 (en)	2003-07-31
BG107469A (bg)	2003-09-30
NO20030472L (no)	2003-03-27
CR6861A (es)	2004-03-11
PE20020337A1 (es)	2002-05-08
HUP0303069A2 (hu)	2004-03-01
JP2008255123A (ja)	2008-10-23
IS6662A (is)	2002-12-19
AU2001270944A1 (en)	2002-02-13
DOP2001000220A (es)	2002-05-15
TNSN01114A1 (fr)	2005-11-10
KR20030019644A (ko)	2003-03-06
ECSP034445A (es)	2003-03-10
NZ523272A (en)	2004-08-27
ZA200300819B (en)	2004-04-20
UY26862A1 (es)	2002-02-28
PL365134A1 (en)	2004-12-27

Publication	Publication Date	Title
EE200300049A (et)	2004-10-15	Imidasooli derivaadid
ATE360620T1 (de)	2007-05-15	Imidazolderivate
NO20025517L (no)	2002-11-18	Triazolderivater
ATE425147T1 (de)	2009-03-15	Imidazolderivate
ATE333445T1 (de)	2006-08-15	Pyrazolderivate
DK1292604T3 (da)	2009-06-15	2-Aminocarbonyl-9H-purinderivater
DK1224180T3 (da)	2003-10-20	Substituerede azoler
ATE288437T1 (de)	2005-02-15	Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
DK1368299T3 (da)	2006-11-27	Substituerede C-cyclohexylmethylaminderivater
AR028602A1 (es)	2003-05-14	Derivados de pirrol
AR028282A1 (es)	2003-04-30	Derivados de aminofenil pirimidona
ATE282021T1 (de)	2004-11-15	Substituierte aminomethyl-phenyl- cyclohexanderivate
DK1322593T3 (da)	2004-10-11	O-substituerede-6-methyl-tramadol-derivater
DK1246791T3 (da)	2005-02-14	Aminomethyl-phenyl-cyklohexanonderivater
DK1322590T3 (da)	2007-09-03	Substituerede 5-amino-1-penten-3-ol-derivater
ATE374776T1 (de)	2007-10-15	Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no)	2002-09-13	2-fenylpyran-4-on-derivater
DK1246793T3 (da)	2005-02-21	Substituerede aminomethyl-phenyl-cyclohexanderivater